Musk announced today the drug test report for June 11, 2025 (issued by a U.S. drug testing agency), which shows that the urine test results for marijuana, cocaine, and other prohibited substances are all negative. This move responds to NASA's review requirements concerning drug involvement by SpaceX contractor executives, at a critical time of controversy over Starlink services in Iran and a 42% decline in Tesla's stock price this year.

Analysis by Brother Qin

Core intention: To mitigate NASA contract risks (review of the $2.9 billion lunar lander project) and stabilize institutional investor confidence in Tesla (the stock price dropped 6% in one day after a live stream showing marijuana use in 2023);

Market impact: Passing the review will eliminate obstacles to SpaceX's potential spin-off listing, boosting Tesla's valuation (current P/E ratio is only 42 times);

Potential hidden dangers: Personal behavior controversies remain unresolved, and if similar incidents occur, it could trigger an SEC investigation into "executive misconduct." Investors may take advantage of a short-term rebound in Tesla's oversold condition, while long-term observation of governance structure reforms is necessary.